

LIST OF INFORMATION DISCLOSED BY APPLICANT
(Use several sheets if necessary)

ATTY. DOCKET NO. 05213-0113	SERIAL NO. 08/468,792	FILING DATE June 6, 1995
APPLICANT Robert D'Amato		GROUP 1205

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	AA	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
W	AA	2,830,991	4/15/58	Keller et al.	546	200	
W	AB	3,560,495	2/2/71	Frankus et al.	544	130	
W	AC	3,563,986	2/16/71	Frankus et al.	544	130	
W	AD	3,625,946	12/7/71	Koch et al.	546	200	
W	AE	3,705,162	12/5/72	Graudums et al.	546	187	
CP	AF	4,552,888	11/12/85	Koppel et al.	514	474	
CP	AG	4,994,443	2/19/91	Folkman et al.	514	56	
CP	AH	5,001,116	3/19/91	Folkman et al.	514	56	
CP	AI	5,021,404	6/4/91	Folkman et al.	514	26	
W	AJ	5,134,127	7/28/92	Stella et al.	514	58	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	NAME	TRANSLATION	
						YES	NO.
CP	AK	58-131978	8/6/83	Japan			
CP	AL	63-119500	5/24/88	Japan			
CP	AM	0325199	7/26/89	EPO			
CP	AN	0357061	3/7/90	EPO			
CP	AO	WO 92/14455	9/3/92	PCT			

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

CP	AP	Fabro, S. et al., "Teratogenic Activity of Thalidomide and Related Compounds," <u>Life Sciences</u> , 3:987-992 (1964).
W	AR	Shealy et al., "D- and L-Thalidomide," <u>Chem. and Indus.</u> , pp. 1030-1031 (June 12, 1965).
W	AS	Folkman, "Tumor Angiogenesis: Therapeutic Implications," <u>The New England Journal of Medicine</u> , 285(21):1182-1186 (11/18/71).
W	AT	Jonsson, N. Ake, et al., "Chemical Structure and Teratogenic Properties," <u>Acta Pharm. Succica</u> , 9:521-542 (1972)

EXAMINER <i>Conrad Hall</i>	DATE CONSIDERED 10/4/96
--------------------------------	----------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered 6/4/92

FORM PTO-1449, Adapted

LIST OF INFORMATION DISCLOSED BY APPLICANT*(Use several sheets if necessary)*

ATTY. DOCKET NO. 05213-0113	SERIAL NO. 08/468,792	FILING DATE June 6, 1995
APPLICANT ROBERT D'AMATO		GROUP

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BA						
	BB						
	BC						
	BD						
	BE						
	BF						
	BG						
	BH						
	BI						
	BJ						
	BK						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	NAME	TRANSLATION YES NO.	
✓	BL	1,182,709	3/4/70	Great Britain	Kwizda		
✓	BM	WO 92/18496	10/29/92	International	Grunenthal GMBH		X
	BN						
	BO						

OTHER REFERENCES *(Including Author, Title, Date, Pertinent Pages, Etc.)*

CP	BP		Jonsson, N. Ake, et al., "Chemical Structure and Teratogenic Properties," <u>Acta Pharm. Succica</u> , 9:431-446 (1972).
CP	BR		Jonsson, N. Ake, et al., "Chemical Structure and Teratogenic Properties," <u>Acta Pharm. Succica</u> , 9:543-562 (1972).
CP	BS		Eriksson, Sven O., "Synthesis and Alkaline Hydrolysis of some N-substituted Phthalimides," <u>Acta Pharm. Succica</u> , 10:63-74 (1973)
WD	BT		Gimbrone et al., "Tumor Growth and Neovascularization: An Experimental Model Using the Rabbit Cornea," <u>J. Nat'l Cancer Institute</u> , 52(2):413-419 (1974).

EXAMINER <i>Carl Dole</i>	DATE CONSIDERED <i>10/4/96</i>
------------------------------	-----------------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered 6/4/92

FORM PTO-1449, Adapted

LIST OF INFORMATION DISCLOSED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.		SERIAL NO.	FILING DATE
05213-0111		08/168,817	December 15, 1993
APPLICANT		GROUP	
Robert D'Amato		1209	
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)			
	CA		Fickentscher, K., "Stereochemical Properties and Teratogenic Activity of Some Tetrahydrophthalimides," <u>Mol. Pharmacology</u> , 13:133-141 (1977).
W	CB		Knighton et al., "Avascular And Vascular Phases Of Tumor Growth In The Chick Embryo," <u>Br. J. Cancer</u> , 35:347-356 (1977).
W	CC		Blaschke, "Chromatographic Separation of Racemic Thalidomide and Teratogenic Activity of its Enantiomers (Chromatographische Racemattrennung von Thalidomid und teratogene Wirkung der Enantiomere)," <u>Drug Research</u> , 29 (II/10): 1640-1642 (1979). (English lang. summary on first page)
W	CD		Muthukkaruppan et al., "Angiogenesis in the Mouse Cornea," <u>Science</u> , 205:1416-1418 (9/28/79).
W	CE		Waters, et al., "Treatment of Ulcerative Colitis with Thalidomide," <u>British Medical Journal</u> , p. 792 (Mar. 24, 1979).
W	CF		Flohe et al., "Studies on the Hypothetical Relationship of Thalidomide-induced Embryopathy and Collagen Biosynthesis," <u>Arzneimittelforschung (GERMANY, WEST)</u> , 31(2):315-20 (1981).
W	CG		Helm, <u>Drug Research</u> , 31 (I/6): 941-949 (1981).
W	CH		Taylor et al., <u>Nature</u> , 297: p. 307 (1982).
W	CI		Belaube et al., "Should Thalidomide be Rehabilitated?," <u>Sem. Hôp. Paris</u> , 59(45):3101-3104 (Dec. 8, 1983).
W	CJ		Folkman et al., <u>Science</u> , 221: p. 719 (1983).
W	CK		Hendler, Sheldon S. et al., "Thalidomide for Autoimmune Disease," <u>Medical Hypotheses</u> , 10:437-443 (1983).
W	CL		Crum et al., <u>Science</u> , 230: 1375 et seq. (1985).
W	CM		Koch, H.P. et al., "Thalidomide and Cogeners as Anti-inflammatory Agents," <u>Progress in Medicinal Chemistry</u> , 22:166-242 (1985).
W	CN		Sidky et al., <u>Cancer Research</u> , 47: pp. 5155-5161 (1987).
W	CO		Srivastava et al., "The Prognostic Significance of Tumor Vascularity in Intermediate-Thickness Skin Melanoma," <u>Am. J. Pathol.</u> , 133:419-423 (1988). (abstract from MEDLINE: Accession no. 06745734)
W	CP		Chen et al., "Plasma Pharmacokinetics and Urinary Excretion of Thalidomide After Oral Dosing in Healthy Male Volunteers," <u>Drug Metabolism and Disposition</u> , 17(4):402-405 (1989).
W	CQ		White et al., <u>New England J. Med.</u> , 320: pp. 1197-1200 (1989).
W	CR		Folkman et al., "Induction of Angiogenesis During the Transition from Hyperplasia to Neoplasia," <u>Nature</u> , 339:58-61 (5/4/89).
W	CS		"Thalidomide," <u>The Merck Index</u> , Eleventh Edition, Budavari et al., eds., Merck & Co., New Jersey, p. 9182 (1989).
W	CT		Eger, K. et al., "Synthesis, Central Nervous System Activity and Teratogenicity of a Homothalidomide," <u>Arzneim.-Forsch/Drug Res.</u> 40 (II. Nr. 10):1073-1075 (1990).
W	CU		Ingber et al., "Synthetic Analogs Of Fumagillin That Inhibit Angiogenesis And Suppress Tumour Growth," <u>Nature</u> , 348:555-557 (12/6/90).
W	CV		Brem et al., <u>Neurosurg.</u> , 74: 441-446 (1991).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


all considered 6/4/97

LIST OF INFORMATION DISCLOSED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.		SERIAL NO.	FILING DATE
05213-0111		08/168,817	December 15, 1993
APPLICANT			GROUP
Robert D'Amato			1209
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)			
CP	DA	Matsuyama, Toshifumi, "Cytokines and HIV infection: is AIDS a Tumor Necrosis Factor Disease?," <u>AIDS</u> , 5(12):1405-1417 (1991).	
ul	DB	Weidner et al., "Tumor Angiogenesis and Metastasis - Correlation in Invasive Breast Carcinoma," <u>N.E.J. Med.</u> , 324(1):1-8 (1991).	
ul	DC	Colville-Nash et al., "Angiogenesis and Rheumoid Arthritis: Pathogenic and Therapeutic Implications," <u>Ann. Rheum. Dis.</u> , 51:919-925 (1992).	
ul	DD	Folkman and Shing, "Angiogenesis," <u>J. Biol. Chem.</u> , 267(16):10931-10934 (1992).	
ul	DE	Schweigerer and Fotsis, "Angiogenesis and angiogenesis inhibitors in paediatric diseases," <u>Eur. J. Pediatr.</u> 151:472-476 (1992).	
or	DF	Torry and Rongish, Angiogenesis in the Uterus: Potential Regulation and Relation to Tumor Angiogenesis," <u>Am. J. Reprod. Immunol.</u> , 27:171-179 (1992).	
ul	DG	Vogelsang et al., "Thalidomide for the Treatment of Chronic Graft-Versus-Host Disease," <u>New England Journal of Medicine</u> , 326:1055-1058 (1992).	
P	DH	Weidner et al., "Angiogenesis in Prostate Carcinoma," <u>Am. J. Path.</u> , 143(2):401-409 (1993).	
ul	DI	D'Amato et al., "Thalidomide is an Inhibitor of Angiogenesis," <u>PNAS USA</u> , 91:4082-4085 (1994).	
ul	DJ	Oikawa et al., "Eponemycin, A Novel Antibiotic, is a Highly Powerful Angiogenesis Inhibitor," <u>Biochem. Biophys. Res. Comm.</u> , 181(3):1070-1076 (Dec. 31, 1991).	
ul	DK	Otsuka et al., "A New Potent Angiogenesis Inhibitor, FR-118487," <u>J. Microb. Biotech.</u> , 1(3):163-168 (1991).	
	DL		
	DM		
	DN		
	DO		
	DP		
	DQ		
	DR		
	DS		
	DT		
	DU		
	DV		

EXAMINER



DATE CONSIDERED

10/4/94

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.